CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • December 21st, 2020 • Seneca Biopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
This Contingent Value Rights Agreement, dated as of _________, 20___ (this “Agreement”), by and among Seneca Biopharma, Inc., a Delaware corporation (“Parent”), [●], as CVR Agent (the “CVR Agent”), and [●], in [its/his/her] capacity as the initial CVR Holders’ Representative (the “CVR Holders’ Representative”).
AGREEMENT AND PLAN OF MERGER among: SENECA BIOPHARMA INC.; TOWNSGATE ACQUISITION SUB 1, INC.; and LEADING BIOSCIENCES, INC. Dated as of December 16, 2020Merger Agreement • December 21st, 2020 • Seneca Biopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of December 16, 2020, by and among Seneca Biopharma, Inc., a Delaware corporation (“PubCo”), Townsgate Acquisition Sub 1, Inc., a Delaware corporation and wholly owned Subsidiary of PubCo (“Merger Sub”), and Leading BioSciences, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Section 1.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 21st, 2020 • Seneca Biopharma, Inc. • Biological products, (no disgnostic substances) • New York
SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of December 16, 2020, by and among Leading BioSciences, Inc., a Delaware corporation, with headquarters located at 5800 Armada Drive, Suite 210, Carlsbad, CA 92008 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyers").
